In pre-clinical studies, blocking IL-8 signaling with the CXCR1/2 small-molecule inhibitors SX-682 or reparixin resulted in increased antitumor immunity and significantly slower tumor growth in gastric cancer [207], pancreatic cancer [224,225], squamous cell carcinoma [226], NSCLC [227], glioma [213] and hepatocellular carcinoma [228]. This evidence concerns the gene CXCR1 and neoplasm.